Clinical trials: Adalimumab
Moderate to Severe Plaque Psoriasis
Documentation of Humira in Psoriasis Patients in Routine Clinical Practice
Safety and Effectiveness of adalimumab (Humira) in Psoriasis Patients in Routine Clinical Practice.
- Trial name
- LOTOS (NCT01077232)
- Where
- 641 sites in Germany
- Volunteers
- 5,442 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
A Study of LAD191 in Adults With Hidradenitis Suppurativa
The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability…
- Trial name
- NCT07151937
- Testing
- LAD191, Adalimumab
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Almirall, S.A.
Rheumatoid Arthritis
Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis
Pharmacokinetic and Safety Study with Adalimumab in Chinese Subjects with Mild Rheumatoid Arthritis
- Trial name
- NCT00650156
- Testing
- adalimumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- AbbVie
Ulcerative Colitis (UC)
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
- Trial name
- LEGACY (NCT01848561)
- Where
- 512 sites in United States, Australia and 19 more
- Volunteers
- 8,250 people
- Sponsor
- AbbVie
Colitis, Ulcerative, Crohn Disease
A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants
The purpose of this study is to describe treatment patterns associated with first-line and second line biologic use (vedolizumab or other biologic) and to describe the real-world clinical effectiveness of the use (first-line and…
- Trial name
- EVOLVE-IBERIA (NCT03710486)
- Where
- 26 sites in Portugal, Spain
- Volunteers
- 409 people
- Sponsor
- Takeda
Pyoderma Gangrenosum
A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
Pyoderma Gangrenosum (PG) is a rapidly progressive disease and presents as painful, single or multiple lesions, with several clinical variants, in different locations, with a nonspecific histology, which makes the diagnosis…
- Trial name
- NCT04750213
- Where
- 46 sites in Japan
- Volunteers
- 60 people
- Sponsor
- AbbVie
Crohn's Disease
An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)
The objective of this observational study was to assess changes in fecal calprotectin levels and its suitability as a monitoring tool in participants with moderate-to-severe Crohn's Disease who were treated with adalimumab.
- Trial name
- FAIR (NCT01759264)
- Volunteers
- 101 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Healthy Subjects
A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon
This is a proof-of-concept study to investigate whether antibodies (guselkumab and adalimumab) delivered directly to the colon can enter the systemic circulation.
- Trial name
- NCT07788807
- Testing
- Adalimumab, Guselkumab, SDL-001
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Surmount Services, Inc.
Rheumatoid Arthritis
Usability of an AI for M923 in Subjects With Moderate to Severe RA
The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)
- Trial name
- NCT02722044
- Testing
- M923, Autoinjector
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Mild to Moderate COVID-19
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19
- Trial name
- COMBAAT (NCT04705844)
- Testing
- Adalimumab
- Sponsor
- Alachua Government Services, Inc.
Rhematoid Arthritis
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with…
- Trial name
- ORAL STRATEGY (NCT02187055)
- Testing
- Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
- Where
- 215 sites in United States, Argentina and 23 more
- Volunteers
- 1,152 people
- Sponsor
- Pfizer
Crohn Disease, Ulcerative Colitis
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic…
- Conditions
- Crohn Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis
- Trial name
- OPALE (NCT05051943)
- Where
- France
- Volunteers
- 754 people
- Sponsor
- Fresenius Kabi
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT01163916
- Where
- 43 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Abbott
Arthritis, Rheumatoid
A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission
The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab in combination with…
- Trial name
- ADMIRE (NCT00808509)
- Testing
- adalimumab, methotrexate
- Where
- 8 sites in Sweden
- Volunteers
- 33 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Uveitis
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.
- Trial name
- NCT02916017
- Where
- 39 sites in Japan
- Volunteers
- 259 people
- Sponsor
- AbbVie
Healthy Volunteers
Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)
This study has been designed as a multicentre, randomised, double-blind study of AVT02 in healthy adult subjects. The study will assess the PK, safety and tolerability of AVT02 compared to EU-Humira and US licenced Humira…
- Trial name
- NCT03849313
- Testing
- Adalimumab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Alvotech Swiss AG
Severe Plaque Psoriasis in Chinese Children
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint…
- Trial name
- NCT07529925
- Testing
- Adalimumab Solution for Injection
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Early Rheumatoid Arthritis
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).
- Trial name
- CONCERTO (NCT01185301)
- Testing
- adalimumab, methotrexate
- Where
- 68 sites in United States, Argentina and 8 more
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Adult Non-infectious Uveitis
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical research on adalimumab. The project plans to enroll 30 subjects. The safety and efficacy of adalimumab injection for adult non-infectious uveitis are being investigated.
- Trial name
- NCT07663331
- Testing
- TyboWe® Adalimumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Axial Spondyloarthritis
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)
The aim of the study is to evaluate the efficacy, safety, immunogenicity, pharmacokinetics and pharmacodynamics of a fixed dose of study drug (BCD-180) in comparison with placebo in patients with active axial spondyloarthritis…
- Trial name
- NCT06333210
- Testing
- anti-TRBV9 monoclonal antibody infusions, Adalimumab subcutaneous injection
- Where
- 32 sites in Belarus, Russia
- Volunteers
- 421 people
- Sponsor
- Biocad